The SMC assesses every newly licensed medicine soon after launch, on the company's own submission. The system's defining rule is simple: no submission, no recommendation. Silence is scored as a no, and health boards act accordingly.
The odds, from 521 novel EMA authorisations 2011–2020
SMC assesses more of what is authorised than any agency here. Scottish dispensing is not yet in the model, so the funnel stops at the decision. Posterior means with 90% credible intervals from our Bayesian pathway model; segment-level odds by technology, disease area and first-in-class status are in the subscription.
The pathway, step by step
Licensing: MHRA (GB-wide)
Licensing is UK-wide; access is not. Scotland's assessment is separate from NICE and starts from the company's submission, normally expected around first marketing.
Engage: plan the SMC submission alongside the NICE dossier: same evidence, different framingSubmission: full or abbreviated
New active substances take a full submission (clinical + economic case); line extensions and some generics qualify for abbreviated review. The economic case is cost-effectiveness based, leaner than NICE's process and faster to decision.
Our data: abbreviated submissions are near-formality (99% accepted)Committee review, with PACE where it matters
The New Drugs Committee reviews, the SMC decides in monthly public meetings. For end-of-life and orphan medicines, a PACE (Patient and Clinician Engagement) meeting feeds committee deliberations. In practice it is the mechanism that moves borderline cases to yes. Ultra-orphan medicines get a distinct pathway with interim acceptance and mandated data collection.
Engage: request PACE whenever eligible; it exists to be usedAccepted, restricted, or not recommended
Nearly half of all acceptances are restricted to a narrower population than the licence. Confidential discounts through the national Patient Access Scheme process are routine, priced against the Scottish budget, not just read across from England.
Our data: 80% of decided full submissions accepted · 46% restrictedResubmission: the normal second act
A not-recommended is revisited with new evidence or a sharper offer: resubmissions run at a 75% acceptance rate. Individual patient access meanwhile flows through PACS Tier 2 requests at health-board level.
Our data: resubmissions accepted at 75%Health boards and formularies
SMC acceptance obliges boards to make the medicine available; area drug and therapeutics committees translate it into local formularies. Uptake speed varies by board; access is national, adoption is local.
What the record actually shows
Who decides what, and when to engage
| Institution | What it decides | Evidence it weighs | When to engage |
|---|---|---|---|
| SMC HTA body | Whether NHSScotland should routinely use the medicine | Clinical case plus cost-effectiveness; patient/clinician testimony via PACE | Submission at launch; PACE for end-of-life/orphan assets |
| New Drugs Committee SMC technical arm | The detailed assessment behind the decision | Methods rigour of the submission | Through submission quality; responses to questions |
| Health boards & ADTCs Local NHS | Formulary adoption; PACS Tier 2 individual requests | Local budget impact, service fit | Post-decision; earlier for service-heavy launches |
| Healthcare Improvement Scotland Parent body | Ultra-orphan framework and process oversight | Framework criteria | When ultra-orphan designation is in play |
| Scottish Government Policy | Funding envelopes and access policy | System-level affordability | Rarely directly; shapes the weather |
The evidence Scotland actually asks for
The NICE dossier, re-cut. The clinical evidence travels; the framing does not. Scottish comparators, Scottish costs, and a leaner economic case tuned to SMC templates beat a forwarded NICE submission.
The human case, formally. PACE gives patient and clinician testimony structured weight for end-of-life and orphan medicines. Evidence of burden and unmet need belongs in the plan, not the appendix.
A Scottish price. Confidential PAS discounts are negotiated for Scotland; assuming the England discount reads across is a common, quiet error.
Where companies get hurt
Planning a Scottish launch?
We build SMC-ready submissions and PACE strategy alongside the NICE case: one evidence base, two systems, both answered. Fixed fees, senior-built.
Talk to us